NHL Clinical Trials

44 recruitingLast updated: June 17, 2026

There are 44 actively recruiting nhl clinical trials across 23 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3. Top locations include Wuhan, Hubei, China, New York, New York, United States, New Brunswick, New Jersey, United States. Updated daily from ClinicalTrials.gov.


NHL Trials at a Glance

44 actively recruiting trials for nhl are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 1 with 23 trials, with the heaviest enrollment activity in Wuhan, New York, and New Brunswick. Lead sponsors running nhl studies include National Cancer Institute (NCI), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and Regeneron Pharmaceuticals.

Treatments under study

About NHL Clinical Trials

Looking for clinical trials for NHL? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new NHL trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about NHL clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 44 trials

Recruiting
Phase 1Phase 2

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Acute Lymphoblastic LeukemiaLymphoma, Non-HodgkinB-cell Lymphoma+8 more
National Cancer Institute (NCI)130 enrolled1 locationNCT05442515
Recruiting
Phase 1

CD45BE-HSPC + CART-45 Cells

Hodgkin LymphomaRichter's TransformationT-cell Non-Hodgkin Lymphoma+1 more
University of Pennsylvania42 enrolled1 locationNCT07451054
Recruiting

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Chronic Lymphocytic Leukemia (CLL)Hairy Cell Leukemia (HCL)Non-Hodgkins Lymphoma (NHL)+2 more
National Cancer Institute (NCI)1,263 enrolled1 locationNCT01087333
Recruiting
Phase 2

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Diffuse Large B Cell LymphomaNHLNon-Hodgkin's Lymphoma+1 more
National Cancer Institute (NCI)132 enrolled1 locationNCT04002947
Recruiting
Phase 1

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Lymphoma, B-CellChronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)+1 more
Umoja Biopharma106 enrolled8 locationsNCT06528301
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)Autoimmune Hemolytic Anemia, AIHA+1 more
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting
Phase 2

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Hodgkin LymphomaB-cell LymphomaRelapsed B-cell NHL
M.D. Anderson Cancer Center36 enrolled1 locationNCT05615636
Recruiting
Phase 1

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

B-cell Non-Hodgkins Lymphoma (B-NHL)
Regeneron Pharmaceuticals107 enrolled20 locationsNCT05685173
Recruiting
Not Applicable

Acupuncture Therapy for Sudden Sensorineural Hearing Loss

Sudden Sensorineural Hearing Loss (SSNHL)
Eye & ENT Hospital of Fudan University256 enrolled1 locationNCT07575334
Recruiting
Early Phase 1

A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma

DLBCL - Diffuse Large B Cell LymphomaFollicular Lymphoma ( FL)B-cell Non Hodgkin Lymphoma (NHL)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology24 enrolled1 locationNCT07548697
Recruiting
Phase 1

SynKIR-310 for Relapsed/Refractory B-NHL

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaDLBCL - Diffuse Large B Cell Lymphoma+23 more
Verismo Therapeutics36 enrolled5 locationsNCT06544265
Recruiting
Phase 3

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma (B-NHL)
Regeneron Pharmaceuticals216 enrolled101 locationsNCT06230224
Recruiting
Phase 2

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

AMLMDSHLH+6 more
Memorial Sloan Kettering Cancer Center31 enrolled1 locationNCT04644016
Recruiting
Phase 1Phase 2

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Diffuse Large B Cell LymphomaFollicular LymphomaMarginal Zone Lymphoma+5 more
Medical College of Wisconsin100 enrolled1 locationNCT04186520
Recruiting
Phase 1

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Arvinas Inc.255 enrolled17 locationsNCT06393738
Recruiting
Phase 1

NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma

Non-Hodgkin Lymphoma (NHL)
NOBO Medicine9 enrolled6 locationsNCT07114367
Recruiting
Phase 1

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

Non-Hodgkin LymphomaMantle Cell Lymphoma (MCL)CNS Lymphoma+1 more
University of Colorado, Denver68 enrolled1 locationNCT05098613
Recruiting
Early Phase 1

Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies

Acute Lymphoblastic Leukemia (ALL), AdultNon-Hodgkin Lymphoma (NHL)
PersonGen BioTherapeutics (Suzhou) Co., Ltd.19 enrolled1 locationNCT07312630
Recruiting
Phase 1

A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

NHL
Haisco Pharmaceutical Group Co., Ltd.110 enrolled1 locationNCT07283796
Recruiting
Not Applicable

SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors

Colon CancerLung Cancer (Diagnosis)Lung Adenocarcinoma+8 more
Barbara Nemesure100 enrolled1 locationNCT07161713